Europe Contract Research Organization (CRO) Market Research Report Forecast to 2030

The growth of the Europe contract research organization (CRO) market is attributed to the increasing R&D expenditure in Europe, the rising number of clinical trials, digital transformation in clinical trials, and growing CRO outsourcing in drug development. However, a shortage of skilled and experienced professionals and stringent regulatory policies are anticipated to hamper the market growth.

A contract research organization also called a Clinical Research Organization (CRO), provides support to the pharmaceutical and biotechnology industries in the form of outsourced pharmaceutical research services (for both drugs and medical devices). CROs also offer the experience of advancing a new drug or device from its inception to FDA marketing approval to their clients without the drug sponsor needing to maintain a staff for these services. CROs range from huge, international full-service businesses to small, niche specialty groups.

The Europe Contract Research Organization (CRO) market is emerging due to factors the increasing R&D expenditure in Europe, the rising number of clinical trials, and the growing CRO outsourcing in drug development. Additionally, the digital transformation in clinical trials will provide growth opportunities for the market in the future. However, the shortage of skilled and experienced professionals and stringent regulatory policies might hamper the market's growth in the forecast period.

Market Segmentation

In terms of Type, Europe Contract research organization is classified into Phase I, phase II, phase III, and Phase IV clinical trial services.

Based on applications the market is classified into Oncology, Cardiovascular, Autoimmune/Inflammation, Central Nervous System (CNS), Dermatology, Infectious Diseases, and Others.

The end-user industry is made up of Pharmaceutical and Biopharmaceutical Companies, Research Laboratories, and Others.

Regional Analysis

The increasing investment in R&D programs, patent expiration in the healthcare sector, and preference for outsourcing activities due to time & cost constraints are key factors anticipated to drive the Europe Contract Research Organization (CRO) market. In addition, increasing government support to research institutes and companies for R&D activities through grants and funds has further boosted the regional market. For instance, in 2021, the European government invested USD 109 billion in medical and health R&D. This is attributed to the high prevalence of chronic conditions, a fast-growing pharmaceutical market, a treatment-naive patient pool, access to a large, favorable, and harmonized regulatory environment, and strong Intellectual Property (IP) and legal Infrastructure. In addition, the availability of skilled professionals having experience with regulations and numerous large-scale, advanced clinical trial centers and specialized disease centers with therapeutic area expertise is further boosting regional growth.

Major Players

Charles River Laboratories, IQVIA, Laboratory Corporation of America Holdings, Thermo Fisher Scientific Inc., and ICON plc.

COVID 19 Impacts

We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

1.1 OVERVIEW

2 MARKET INTRODUCTION

2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
2.5 ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.4 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
- 3.6.1 BOTTOM-UP APPROACH
- 3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION

4 MARKET DYNAMICS

4.1 OVERVIEW
4.2 DRIVERS
- 4.2.1 INCREASING R&D EXPENDITURE IN EUROPE
- 4.2.2 RISING NUMBER OF CLINICAL TRIALS
- 4.2.3 GROWING CRO OUTSOURCING IN DRUG DEVELOPMENT
4.3 RESTRAINTS
- 4.3.1 SHORTAGE OF SKILLED AND EXPERIENCED PROFESSIONALS
- 4.3.2 STRINGENT REGULATORY POLICIES
4.4 OPPORTUNITY
- 4.4.1 DIGITAL TRANSFORMATION IN CLINICAL TRIALS

5 MARKET FACTOR ANALYSIS

5.1 VALUE CHAIN ANALYSIS
- 5.1.1 CUSTOMER ACQUISITION (PREPURCHASE QUERY)
- 5.1.2 SERVICE CUSTOMIZATION
- 5.1.3 CUSTOMER PURCHASE SUPPORT
- 5.1.4 CUSTOMER FULFILMENT & POST-PURCHASE SUPPORT
5.2 PORTER'S FIVE FORCES MODEL
- 5.2.1 THREAT OF NEW ENTRANTS
- 5.2.2 BARGAINING POWER OF SUPPLIERS
- 5.2.3 THREAT OF SUBSTITUTES
- 5.2.4 BARGAINING POWER OF BUYERS
- 5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON CONTRACT RESEARCH ORGANIZATION MARKET
- 5.3.1 IMPACT ON SUPPLY CHAIN
- 5.3.2 IMPACT ON PRICING
- 5.3.3 IMPACT ON KEY PLAYERS

6 EUROPE CONTRACT RESEARCH ORGANIZATION (CRO) MARKET, BY TYPE

6.1 OVERVIEW
6.2 PHASE I TRIAL SERVICES
6.3 PHASE II TRIAL SERVICES
6.4 PHASE III TRIAL SERVICES
6.5 PHASE IV TRIAL SERVICES

7 EUROPE CONTRACT RESEARCH ORGANIZATION (CRO) MARKET, BY APPLICATION

7.1 OVERVIEW
7.2 ONCOLOGY
7.3 CARDIOVASCULAR
7.4 AUTOIMMUNE/INFLAMMATION
7.5 CENTRAL NERVOUS SYSTEM (CNS)
7.6 DERMATOLOGY
7.7 INFECTIOUS DISEASES
7.8 OTHERS

8 EUROPE CONTRACT RESEARCH ORGANIZATION (CRO) MARKET, BY END USER

8.1 OVERVIEW
8.2 PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES
8.3 RESEARCH LABORATORIES
8.4 OTHERS

9 EUROPE CONTRACT RESEARCH ORGANIZATION (CRO) MARKET, BY COUNTRY

9.1 OVERVIEW
9.2 GERMANY
9.3 AUSTRIA
9.4 SWITZERLAND
9.5 REST OF EUROPE

10 COMPETITIVE LANDSCAPE

10.1 OVERVIEW
10.2 COMPETITIVE BENCHMARKING
10.3 MAJOR GROWTH STRATEGY IN THE EUROPE CONTRACT RESEACH ORGANIZATION (CRO) MARKET
10.4 THE LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN EUROPE CONTRACT RESEACH ORGANIZATION (CRO) MARKET
10.5 KEY DEVELOPMENT ANALYSIS
10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 10.6.1 ACQUISITION
- 10.6.2 COLLABORATION
- 10.6.3 PARTNERSHIP
- 10.6.4 PRODUCT/SERVICE LAUNCH
10.7 MAJOR PLAYERS FINANCIAL MATRIX
- 10.7.1 SALES, 2021

11 COMPANY PROFILES

11.1 THERMO FISHER SCIENTIFIC INC.
- 11.1.1 COMPANY OVERVIEW
- 11.1.2 FINANCIAL OVERVIEW
- 11.1.3 PRODUCT/SERVICE OFFERED
- 11.1.4 KEY DEVELOPMENTS
- 11.1.5 SWOT ANALYSIS
- 11.1.6 KEY STRATEGIES
11.2 LABORATORY CORPORATION OF AMERICA HOLDINGS
- 11.2.1 COMPANY OVERVIEW
- 11.2.2 FINANCIAL OVERVIEW
- 11.2.3 PRODUCT/SERVICE OFFERED
- 11.2.4 KEY DEVELOPMENTS
- 11.2.5 KEY STRATEGIES
11.3 ICON PLC
- 11.3.1 COMPANY OVERVIEW
- 11.3.2 FINANCIAL OVERVIEW
- 11.3.3 PRODUCT/SERVICE OFFERED
- 11.3.4 KEY DEVELOPMENTS
- 11.3.5 SWOT ANALYSIS
- 11.3.6 KEY STRATEGIES
11.4 CLARIO
- 11.4.1 COMPANY OVERVIEW
- 11.4.2 FINANCIAL OVERVIEW
- 11.4.3 PRODUCT/SERVICE OFFERED
- 11.4.4 KEY DEVELOPMENTS
- 11.4.5 KEY STRATEGIES
11.5 GALSER SA
- 11.5.1 COMPANY OVERVIEW
- 11.5.2 FINANCIAL OVERVIEW
- 11.5.3 PRODUCT/SERVICE OFFERED
- 11.5.4 KEY DEVELOPMENTS
- 11.5.5 KEY STRATEGIES
11.6 CHARLES RIVER LABORATORIES
- 11.6.1 COMPANY OVERVIEW
- 11.6.2 FINANCIAL OVERVIEW
- 11.6.3 PRODUCTS OFFERED
- 11.6.4 KEY DEVELOPMENTS
- 11.6.5 SWOT ANALYSIS
- 11.6.6 KEY STRATEGIES
11.7 PAREXEL INTERNATIONAL CORPORATION.
- 11.7.1 COMPANY OVERVIEW
- 11.7.2 FINANCIAL OVERVIEW
- 11.7.3 PRODUCTS OFFERED
- 11.7.4 KEY DEVELOPMENTS
- 11.7.5 KEY STRATEGIES
11.8 IQVIA
- 11.8.1 COMPANY OVERVIEWS
- 11.8.2 FINANCIAL OVERVIEW
- 11.8.3 PRODUCTS OFFERED
- 11.8.4 KEY DEVELOPMENTS
- 11.8.5 SWOT ANALYSIS
- 11.8.6 KEY STRATEGIES
11.9 SYNEOS HEALTH
- 11.9.1 COMPANY OVERVIEW
- 11.9.2 FINANCIAL OVERVIEW
- 11.9.3 PRODUCTS OFFERED
- 11.9.4 KEY DEVELOPMENTS
- 11.9.5 SWOT ANALYSIS
- 11.9.6 KEY STRATEGIES
11.10 QUANTICATE
- 11.10.1 COMPANY OVERVIEW
- 11.10.2 FINANCIAL OVERVIEW
- 11.10.3 PRODUCTS OFFERED
- 11.10.4 KEY DEVELOPMENTS
- 11.10.5 KEY STRATEGIES

12 APPENDIX

12.1 REFERENCES
12.2 RELATED REPORTS

LIST OF TABLES

TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS 15
TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 18
TABLE 3 EUROPE CONTRACT RESEARCH ORGANIZATION (CRO) MARKET, BY TYPE, 2018-2030 (USD MILLION) 35
TABLE 4 EUROPE CONTRACT RESEARCH ORGANIZATION (CRO) MARKET, FOR PHASE I TRIAL SERVICES, BY COUNTRY, 2018-2030 (USD MILLION) 36
TABLE 5 EUROPE CONTRACT RESEARCH ORGANIZATION (CRO) MARKET, FOR PHASE II TRIAL SERVICES, BY COUNTRY, 2018-2030 (USD MILLION) 36
TABLE 6 EUROPE CONTRACT RESEARCH ORGANIZATION (CRO) MARKET, FOR PHASE III TRIAL SERVICES, BY COUNTRY, 2018-2030 (USD MILLION) 37
TABLE 7 EUROPE CONTRACT RESEARCH ORGANIZATION (CRO) MARKET, FOR PHASE IV TRIAL SERVICES, BY COUNTRY, 2018-2030 (USD MILLION) 37
TABLE 8 EUROPE CONTRACT RESEARCH ORGANIZATION (CRO) MARKET, BY APPLICATION, 2018-2030 (USD MILLION) 39
TABLE 9 EUROPE CONTRACT RESEARCH ORGANIZATION (CRO) MARKET, FOR ONCOLOGY, BY COUNTRY, 2018-2030 (USD MILLION) 40
TABLE 10 EUROPE CONTRACT RESEARCH ORGANIZATION (CRO) MARKET, FOR CARDIOVASCULAR, BY COUNTRY, 2018-2030 (USD MILLION) 40
TABLE 11 EUROPE CONTRACT RESEARCH ORGANIZATION (CRO) MARKET, FOR AUTOIMMUNE/INFLAMMATION, BY COUNTRY, 2018-2030 (USD MILLION) 41
TABLE 12 EUROPE CONTRACT RESEARCH ORGANIZATION (CRO) MARKET, FOR CENTRAL NERVOUS SYSTEM (CNS), BY COUNTRY, 2018-2030 (USD MILLION) 41
TABLE 13 EUROPE CONTRACT RESEARCH ORGANIZATION (CRO) MARKET, FOR DERMATOLOGY, BY COUNTRY, 2018-2030 (USD MILLION) 42
TABLE 14 EUROPE CONTRACT RESEARCH ORGANIZATION (CRO) MARKET, FOR INFECTIOUS DISEASES, BY COUNTRY, 2018-2030 (USD MILLION) 42
TABLE 15 EUROPE CONTRACT RESEARCH ORGANIZATION (CRO) MARKET, FOR OTHERS, BY COUNTRY, 2018-2030 (USD MILLION) 43
TABLE 16 EUROPE CONTRACT RESEARCH ORGANIZATION (CRO) MARKET, BY END USER, 2018-2030 (USD MILLION) 45
TABLE 17 EUROPE CONTRACT RESEARCH ORGANIZATION (CRO) MARKET, FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2030 (USD MILLION) 46
TABLE 18 EUROPE CONTRACT RESEARCH ORGANIZATION (CRO) MARKET, FOR RESEARCH LABORATORIES, BY COUNTRY, 2018-2030 (USD MILLION) 46
TABLE 19 EUROPE CONTRACT RESEARCH ORGANIZATION (CRO) MARKET, FOR OTHERS, BY COUNTRY, 2018-2030 (USD MILLION) 47
TABLE 20 EUROPE CONTRACT RESEARCH ORGANIZATION (CRO) MARKET, BY COUNTRY, 2018-2030 (USD MILLION) 49
TABLE 21 EUROPE CONTRACT RESEARCH ORGANIZATION (CRO) MARKET, BY TYPE, 2018-2030 (USD MILLION) 49
TABLE 22 EUROPE CONTRACT RESEARCH ORGANIZATION (CRO) MARKET, BY APPLICATION, 2018-2030 (USD MILLION) 50
TABLE 23 EUROPE CONTRACT RESEARCH ORGANIZATION (CRO) MARKET, BY END USER, 2018-2030 (USD MILLION) 50
TABLE 24 GERMANY: CONTRACT RESEARCH ORGANIZATION (CRO) MARKET, BY TYPE, 2018-2030 (USD MILLION) 51
TABLE 25 GERMANY: CONTRACT RESEARCH ORGANIZATION (CRO) MARKET, BY APPLICATION, 2018-2030 (USD MILLION) 51
TABLE 26 GERMANY: CONTRACT RESEARCH ORGANIZATION (CRO) MARKET, BY END USER, 2018-2030 (USD MILLION) 51
TABLE 27 AUSTRIA: CONTRACT RESEARCH ORGANIZATION (CRO) MARKET, BY TYPE, 2018-2030 (USD MILLION) 52
TABLE 28 AUSTRIA: CONTRACT RESEARCH ORGANIZATION (CRO) MARKET, BY APPLICATION, 2018-2030 (USD MILLION) 52
TABLE 29 AUSTRIA: CONTRACT RESEARCH ORGANIZATION (CRO) MARKET, BY END USER, 2018-2030 (USD MILLION) 52
TABLE 30 SWITZERLAND: CONTRACT RESEARCH ORGANIZATION (CRO) MARKET, BY TYPE, 2018-2030 (USD MILLION) 53
TABLE 31 SWITZERLAND: CONTRACT RESEARCH ORGANIZATION (CRO) MARKET, BY APPLICATION, 2018-2030 (USD MILLION) 53
TABLE 32 SWITZERLAND: CONTRACT RESEARCH ORGANIZATION (CRO) MARKET, BY END USER, 2018-2030 (USD MILLION) 53
TABLE 33 REST OF EUROPE: CONTRACT RESEARCH ORGANIZATION (CRO) MARKET, BY TYPE, 2018-2030 (USD MILLION) 54
TABLE 34 REST OF EUROPE: CONTRACT RESEARCH ORGANIZATION (CRO) MARKET, BY APPLICATION, 2018-2030 (USD MILLION) 54
TABLE 35 REST OF EUROPE: CONTRACT RESEARCH ORGANIZATION (CRO) MARKET, BY END USER, 2018-2030 (USD MILLION) 54
TABLE 36 MAJOR PLAYERS IN THE EUROPE CONTRACT RESEARCH ORGANIZATION (CRO) MARKET 55
TABLE 37 MOST ACTIVE PLAYERS IN THE EUROPE CONTRACT RESEACH ORGANIZATION (CRO) MARKET 57
TABLE 38 ACQUISITION 59
TABLE 39 COLLABORATION 59
TABLE 40 PARTNERSHIP 60
TABLE 41 PRODUCT/SERVICE LAUNCH 60
TABLE 42 THERMO FISHER SCIENTIFIC INC.: SERVICES OFFERED 63
TABLE 43 LABORATORY CORPORATION OF AMERICA HOLDINGS: SERVICES OFFERED 66
TABLE 44 LABORATORY CORPORATION OF AMERICA HOLDINGS: KEY DEVELOPMENTS 67
TABLE 45 ICON PLC: SERVICES OFFERED 69
TABLE 46 ICON PLC: KEY DEVELOPMENTS 69
TABLE 47 CLARIO: SERVICES OFFERED 71
TABLE 48 GALSER SA: SERVICES OFFERED 73
TABLE 49 CHARLES RIVER LABORATORIES.: SERVICES OFFERED 77
TABLE 50 CHARLES RIVER LABORATORIES: KEY DEVELOPMENTS 77
TABLE 51 PAREXEL INTERNATIONAL CORPORATION.: SERVICES OFFERED 79
TABLE 52 PAREXEL INTERNATIONAL CORPORATION.: KEY DEVELOPMENTS 80
TABLE 53 IQVIA: PRODUCTS OFFERED 82
TABLE 54 IQVIA: KEY DEVELOPMENTS 83
TABLE 55 SYNEOS HEALTH.: SERVICES OFFERED 85
TABLE 56 QUANTICATE: SERVICES OFFERED 87
TABLE 57 QUANTICATE: KEY DEVELOPMENTS 88

LIST OF FIGURES

FIGURE 1 MARKET SYNOPSIS 12
FIGURE 2 EUROPE CONTRACT RESEARCH ORGANIZATION (CRO) MARKET STRUCTURE 14
FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES 21
FIGURE 4 MARKET DYNAMICS: EUROPE CONTRACT RESEARCH ORGANIZATION (CRO) MARKET 24
FIGURE 5 DRIVER IMPACT ANALYSIS 26
FIGURE 6 RESTRAINT IMPACT ANALYSIS 27
FIGURE 7 VALUE CHAIN ANALYSIS: EUROPE CONTRACT RESEARCH ORGANIZATION (CRO) MARKET 29
FIGURE 8 PORTER'S FIVE FORCES ANALYSIS: EUROPE CONTRACT RESEARCH ORGANIZATION (CRO) MARKET 31
FIGURE 9 EUROPE CONTRACT RESEARCH ORGANIZATION (CRO), BY TYPE, 2021 & 2030 (USD MILLION) 35
FIGURE 10 EUROPE CONTRACT RESEARCH ORGANIZATION (CRO) MARKET, BY APPLICATION, 2021 & 2030 (USD MILLION) 39
FIGURE 11 EUROPE CONTRACT RESEARCH ORGANIZATION (CRO) MARKET, BY END USER, 2021 & 2030 (USD MILLION) 45
FIGURE 12 EUROPE CONTRACT RESEARCH ORGANIZATION (CRO) MARKET, BY COUNTRY, 2021 & 2030 (USD MILLION) 49
FIGURE 13 BENCHMARKING OF MAJOR COMPETITORS 56
FIGURE 14 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE CONTRACT RESEACH ORGANIZATION (CRO) MARKET 57
FIGURE 15 EUROPE CONTRACT RESEACH ORGANIZATION (CRO) MARKET: COMPETITIVE LANDSCAPE 58
FIGURE 16 SALES, 2021 (USD MILLION) 61
FIGURE 17 THERMO FISHER SCIENTIFIC INC.: FINANCIAL OVERVIEW 63
FIGURE 18 THERMO FISHER SCIENTIFIC INC.: SWOT ANALYSIS 64
FIGURE 19 LABORATORY CORPORATION OF AMERICA HOLDINGS: FINANCIAL OVERVIEW SNAPSHOT 66
FIGURE 20 ICON PLC: FINANCIAL OVERVIEW SNAPSHOT 68
FIGURE 21 ICON PLC: SWOT ANALY 70
FIGURE 22 CHARLES RIVER LABORATORIES FINANCIAL OVERVIEW SNAPSHOT 76
FIGURE 23 CHARLES RIVER LABORATORIES: SWOT ANALYSIS 78
FIGURE 24 IQVIA: FINANCIAL OVERVIEW SNAPSHOT 82
FIGURE 25 IQVIA: SWOT ANALYSIS 83
FIGURE 26 SYNEOS HEALTH: FINANCIAL OVERVIEW SNAPSHOT 85
FIGURE 27 SYNEOS HEALTH: SWOT ANALYSIS 86